Frontiers in Immunology (May 2022)

Longitudinal Dynamics of Cellular Responses in Recovered COVID-19 Patients

  • Meng-Li Cheng,
  • Hui-Ying Liu,
  • Chao Zhou,
  • Rui-Ting Li,
  • Jing Zheng,
  • Yan-Hong Qin,
  • Ning Yang,
  • Yue Zhang,
  • Juan-Juan Huang,
  • Zhu Zhu,
  • Qing-Yu Meng,
  • Guo-Qing Wang,
  • Hui Zhao,
  • Yun Chen,
  • Chang-Qing Bai,
  • Cheng-Feng Qin,
  • Fan Li,
  • Fan Li

DOI
https://doi.org/10.3389/fimmu.2022.911859
Journal volume & issue
Vol. 13

Abstract

Read online

Safe and effective vaccines and therapeutics based on the understanding of antiviral immunity are urgently needed to end the COVID-19 pandemic. However, the understanding of these immune responses, especially cellular immune responses to SARS-CoV-2 infection, is limited. Here, we conducted a cohort study of COVID-19 patients who were followed and had blood collected to characterize the longitudinal dynamics of their cellular immune responses. Compared with healthy controls, the percentage of activation of SARS-CoV-2 S/N-specific T cells in recovered patients was significantly higher. And the activation percentage of S/N-specific CD8+ T cells in recovered patients was significantly higher than that of CD4+ T cells. Notably, SARS-CoV-2 specific T-cell responses were strongly biased toward the expression of Th1 cytokines, included the cytokines IFNγ, TNFα and IL2. Moreover, the secreted IFNγ and IL2 level in severe patients was higher than that in mild patients. Additionally, the number of IFNγ-secreting S-specific T cells in recovered patients were higher than that of N-specific T cells. Overall, the SARS-CoV-2 S/N-specific T-cell responses in recovered patients were strong, and virus-specific immunity was present until 14-16 weeks after symptom onset. Our work provides a basis for understanding the immune responses and pathogenesis of COVID-19. It also has implications for vaccine development and optimization and speeding up the licensing of the next generation of COVID-19 vaccines.

Keywords